Results for the Three Months Ended June 30, 2023

Aug 10, 2023

This datum is based on the data as of June 30, 2023. The opinion and forecast described here is based on our judgment at that time and may possibly be changed without notice.

  1. Operating results for the three months ended June 30, 2023
  2. FY2024 earnings forecasts

1

1. Summary of Consolidated Financial results for the Three Months Ended June 2023

Million yen

FY2023 1Q

FY2024 1Q

Change

Change Ratio

Amount

Net Sales

5,647

6,311

663

11.8%

Operating

165

139

305

-

Income

Operating

2.9%

2.2%

-

-

Income Margin

Ordinary

181

571

390

215.3%

Income

Net Income

21

423

402

1893.6%

Attributable to Owners

of the Parent

FY2023 1Q: 1US$JPY129.0

2

FY2024 1Q: 1US$JPY138.8

1. Highlight

  • Net sales increased YoY due to a recovery in vehicle sales due to the easing of semiconductor shortages, the start of full-scale production for medical equipment at the new Tennessee factory, favorable sales for aircraft, and the effects of price increases and yen depreciation.
  • Despite rising personnel and energy costs, operating profit increased YoY due to the above-mentioned revenue growth effect and the full-fledged start of operations at the new Tennessee plant.
  • Ordinary income and net income increased year-on-year due to foreign exchange gains from the depreciation of the yen.

3

1. Quarterly Transition of Sales and Income(Consolidated)

Million yen

Net Sales(Left axis)

Operationg Income(Right axis)

Million yen

8,000

500

6,235

6,309

6,436

6,311

5,439

5,540

5,647

200

5,412

5,330

139

104

66

49

48

4,000

-21

0

-72

-165

0

1Q

2Q

3Q

4Q

1Q

2Q

3Q

4Q

-500

1Q

FY22

FY23

FY24

FY2023 1Q: 1US$JPY129.0

4

FY2024 1Q: 1US$JPY138.8

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Advanex Inc. published this content on 10 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 August 2023 07:22:31 UTC.